-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Upgrades Kyverna Therapeutics to Buy, Raises Price Target to $5

Benzinga·05/27/2025 10:56:59
Listen to the news
HC Wainwright & Co. analyst Mitchell Kapoor upgrades Kyverna Therapeutics (NASDAQ:KYTX) from Neutral to Buy and raises the price target from $4 to $5.